Neumedicines Names David L. Morash President and Chief Strategy Officer

PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapeutics, announces the appointment of David L. Morash as President and to the newly created position of Chief Strategy Officer, effective immediately. Mr. Morash continues to serve on the Company's Board of Directors and retains responsibilities as Chief Financial Officer. Neumedicines founder Lena A. Basile, Ph.D., J.D., continues as Chief Executive Officer and Chair of the Board.

"This is an exceedingly exciting time at Neumedicines as we prepare for multiple clinical studies to evaluate HemaMax™'s (recombinant human interleukin-12 (rHuIL-12)) ability to re-ignite the compromised immune systems of patients undergoing debilitating and toxic cancer therapies," said Dr. Basile. "Dave has taken a leadership role in advancing our business strategy over the past several years and his new titles better reflect his ongoing responsibilities to our Company."

"I firmly believe that HemaMax can improve the treatment of patients with cancer and am delighted to be a part of the team focused on bringing this important product to market," said Mr. Morash.

Mr. Morash has more than 30 years of senior-level financial and executive experience. Prior to joining Neumedicines, he was Chief Financial Officer of ISE Corporation, where he was instrumental in fundraising and in preparations for its initial public offering; and President, Chief Operating Officer and Chief Financial Officer of Axesstel, Inc., a publicly traded company that he helped to take public. He also served as Executive Vice President and Chief Financial Officer of publicly traded Remec; Executive Vice President of Wireless Knowledge, a joint venture between Qualcomm and Microsoft; and Executive Vice President and Chief Financial Officer of Safeskin Corporation, a medical device company rated by Forbes as the Best Small Company in the U.S. Mr. Morash is cofounder and board member of privately held California Safe Soil, LLC. He received his MBA and BA from Columbia University.

About HemaMax™

HemaMax™ holds considerable value and promise playing a central role in linking and regulating both innate (early nonspecific) and adaptive (late specific) immunity, while also having a critical role in hematopoietic cell-to-cell signaling. HemaMax™ is being developed for various indications in oncology, including acute myeloid leukemia (AML), melanoma, cutaneous T cell lymphoma (CTCL), ovarian cancer, pancreatic cancer, and other immunotherapy applications, as well as providing hematopoietic support. Neumedicines is also developing HemaMax™ as a treatment for the hematopoietic syndrome of acute radiation syndrome.

About Neumedicines Inc.

Neumedicines Inc. is a biotherapeutics company focused on developing and commercializing innovative and proprietary products and approaches for the treatment of various clinical indications that address unmet clinical and societal needs in the fields of oncology, immunology and hematology. The company operates from its headquarters and laboratories in Pasadena, Calif.

For more information, visit: http://www.neumedicines.com.

Follow Neumedicines on Twitter: @Neumedicines.

Follow Neumedicines on LinkedIn: http://www.linkedin.com/company/neumedicines.

Contacts

At the Company:
Neumedicines Inc.
David Morash, +1-626-844-0438
or
Investor/Media Contact:
Financial Profiles, Inc.
Jody Cain, +1-310-622-8227

 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.